Chandigarh Herald

DelveInsight’s “Fragile X Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Fragile X Syndrome, historical and forecasted epidemiology as well as the Fragile X Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Fragile X Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fragile X Syndrome Market Forecast

Some of the key facts of the Fragile X Syndrome Market Report: 

• The Fragile X Syndrome market size was valued approximately USD 45 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The total diagnosed prevalent population of Fragile X Syndrome in the 7MM was estimated to be around 120,926 in 2021. Additionally, there was a diagnosed prevalent population of 69,798 cases of FXS in the United States
• Among the gender-specific prevalent cases, in 2021, there were nearly 41,373 cases of Fragile X Syndrome in males and nearly 28,425 cases in females, in the United States
• The most number of diagnosed prevalent cases of Fragile X Syndrome (FXS) were recorded in the United States
• Key Fragile X Syndrome Companies: Zynerba Pharmaceuticals, Confluence Pharmaceuticals, Tetra Therapeutics, Neuren Pharmaceuticals, Healx, Alcobra Ltd., Seaside Therapeutics, Inc., Novartis, Marinus Pharmaceuticals, Neuren Pharmaceuticals Limited, Hoffmann-La Roche, Neuropharm, and others
• Key Fragile X Syndrome Therapies: Zygel, Acamprosate, BPN14770, Trofinetide, Sulindac (HLX-0201), MG01CI, ZYN002, arbaclofen, AFQ056, Ganaxolone, NNZ-2566, RO4917523, NPL-2009, and others
• The Fragile X Syndrome epidemiology based on gender analyzed that males are affected more as compared to females, in the case of Fragile X Syndrome (FXS)
• The Fragile X Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fragile X Syndrome pipeline products will significantly revolutionize the Fragile X Syndrome market dynamics.

Fragile X Syndrome Overview

Fragile X Syndrome (FXS) is a genetic disease due to a CGG trinucleotide expansion, named full mutation (greater than 200 CGG repeats), in the fragile X mental retardation 1 gene locusXq27.3. It leads to a hyper methylated region in the gene promoter, therefore, silencing it and lowering the expression levels of the fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation.

Get a Free sample for the Fragile X Syndrome Market Report –

https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market

Fragile X Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Fragile X Syndrome Epidemiology Segmentation:

The Fragile X Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Fragile X Syndrome
• Prevalent Cases of Fragile X Syndrome by severity
• Gender-specific Prevalence of Fragile X Syndrome
• Diagnosed Cases of Episodic and Chronic Fragile X Syndrome

Download the report to understand which factors are driving Fragile X Syndrome epidemiology trends @ Fragile X Syndrome Epidemiology Forecast

Fragile X Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fragile X Syndrome market or expected to get launched during the study period. The analysis covers Fragile X Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Fragile X Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Fragile X Syndrome Therapies and Key Companies

• Zygel: Zynerba Pharmaceuticals
• Acamprosate: Confluence Pharmaceuticals
• BPN14770: Tetra Therapeutics
• Trofinetide: Neuren Pharmaceuticals
• Sulindac (HLX-0201): Healx
• MG01CI: Alcobra Ltd.
• ZYN002: Zynerba Pharmaceuticals, Inc.
• arbaclofen: Seaside Therapeutics, Inc.
• AFQ056: Novartis
• Ganaxolone: Marinus Pharmaceuticals
• NNZ-2566: Neuren Pharmaceuticals Limited
• RO4917523: Hoffmann-La Roche
• NPL-2009: Neuropharm

Discover more about therapies set to grab major Fragile X Syndrome market share @ Fragile X Syndrome Treatment Market

Fragile X Syndrome Market Drivers

• Funding and cooperation of various organizations
• Identification of the potential targets by animal models
• Strengthening the molecular basis of FXS

Fragile X Syndrome Market Barriers

• Failure of Clinical Trials
• Expensive Diagnostic Procedures

Scope of the Fragile X Syndrome Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Fragile X Syndrome Companies: Zynerba Pharmaceuticals, Confluence Pharmaceuticals, Tetra Therapeutics, Neuren Pharmaceuticals, Healx, Alcobra Ltd., Seaside Therapeutics, Inc., Novartis, Marinus Pharmaceuticals, Neuren Pharmaceuticals Limited, Hoffmann-La Roche, Neuropharm, and others
• Key Fragile X Syndrome Therapies: Zygel, Acamprosate, BPN14770, Trofinetide, Sulindac (HLX-0201), MG01CI, ZYN002, arbaclofen, AFQ056, Ganaxolone, NNZ-2566, RO4917523, NPL-2009, and others
• Fragile X Syndrome Therapeutic Assessment: Fragile X Syndrome current marketed and Fragile X Syndrome emerging therapies
• Fragile X Syndrome Market Dynamics: Fragile X Syndrome market drivers and Fragile X Syndrome market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Fragile X Syndrome Unmet Needs, KOL’s views, Analyst’s views, Fragile X Syndrome Market Access and Reimbursement 

To know more about Fragile X Syndrome companies working in the treatment market, visit @ Fragile X Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Fragile X Syndrome Market Report Introduction

2. Executive Summary for Fragile X Syndrome

3. SWOT analysis of Fragile X Syndrome

4. Fragile X Syndrome Patient Share (%) Overview at a Glance

5. Fragile X Syndrome Market Overview at a Glance

6. Fragile X Syndrome Disease Background and Overview

7. Fragile X Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Fragile X Syndrome 

9. Fragile X Syndrome Current Treatment and Medical Practices

10. Fragile X Syndrome Unmet Needs

11. Fragile X Syndrome Emerging Therapies

12. Fragile X Syndrome Market Outlook

13. Country-Wise Fragile X Syndrome Market Analysis (2019–2032)

14. Fragile X Syndrome Market Access and Reimbursement of Therapies

15. Fragile X Syndrome Market Drivers

16. Fragile X Syndrome Market Barriers

17.  Fragile X Syndrome Appendix

18. Fragile X Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services